JP4102461B2 - Antipyretic - Google Patents
Antipyretic Download PDFInfo
- Publication number
- JP4102461B2 JP4102461B2 JP16997697A JP16997697A JP4102461B2 JP 4102461 B2 JP4102461 B2 JP 4102461B2 JP 16997697 A JP16997697 A JP 16997697A JP 16997697 A JP16997697 A JP 16997697A JP 4102461 B2 JP4102461 B2 JP 4102461B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- antipyretic
- nanten
- acetaminophen
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
【0001】
【発明の属する技術分野】
本発明は、解熱剤に関する。
【0002】
【従来の技術及び発明が解決しようとする課題】
南天は古くから様々な薬効が知られ、その果実や葉は民間薬として重用されている。特に、果実に含まれるドメスチンは知覚神経及び末梢神経麻痺作用を有し、喘息、百日咳、気管支炎等のせき止めに効果のあることが知られており、南天実を配合した鎮咳用シロップ剤や喉用錠剤が市販されている。
また、近年では、南天実中に存在するナンテニンが交感神経遮断作用を有し、血圧降下剤として有効であることが報告されている(特開昭58−183617号公報)。
しかしながら、南天実が解熱作用を有することは全く知られていない。
【0003】
一方、従来より解熱剤としては様々な薬剤が用いられてきたが、化学合成により得られた物質がほとんどであり、ねむけ、消化器障害などの副作用が避けられないという欠点を有していた。
【0004】
従って、本発明の目的は、優れた解熱作用を有するとともに安全性の高い薬剤を提供することにある。
【0005】
【課題を解決するための手段】
斯かる実状に鑑み、本発明者は鋭意研究を行った結果、南天抽出物が持続的な解熱作用を有することを見出した。更にアセトアミノフェンあるいはイブプロフェンと併用すれば、相乗的な解熱作用を発現することを見出し、本発明を完成した。
【0006】
すなわち、本発明は南天抽出物を有効成分とする解熱剤を提供するものである。
また、本発明は南天抽出物及びアセトアミノフェンを有効成分とする解熱剤を提供するものである。
更に、本発明は南天抽出物及びイブプロフェンを有効成分とする解熱剤を提供するものである。
【0007】
【発明の実施の形態】
本発明に用いられる南天抽出物としては、南天の実や葉の抽出物が挙げられるが、特に南天実抽出物が好ましい。ここで南天実としては、白南天実又は赤南天実のいずれを用いてもよい。
南天抽出物は、水、熱水、有機溶媒等を用いて常法に従って得ることができるが、例えば、乾燥させた南天実をエタノール、水、熱水、含水エタノール等で抽出することにより得られる。南天実を含水エタノール、特に30%エタノール水溶液で抽出したものが好ましい。
【0008】
また、本発明においては南天抽出物とアセトアミノフェン又はイブプロフェンとを併用すれば、相乗的な解熱作用が得られる。南天抽出物(原生薬換算)とアセトアミノフェンの好ましい配合比は、重量比で5000:1〜1:100であり、より好ましい配合比は500:1〜1:10である。また南天抽出物(原生薬換算)とイブプロフェンの好ましい配合比は、重量比で5000:1〜1:60であり、より好ましい配合比は500:1〜1:6である。
本発明の解熱剤は、必須成分の他、薬学的に許容される担体、例えば賦形剤、結合剤、増量剤、崩壊剤、界面活性剤、滑沢剤、分散剤、緩衝剤、保存剤、矯味剤、香料等を適宜組み合わせて用いることができる。またその投与形態としては、例えば錠剤、カプセル剤、顆粒剤、散剤、液剤、シロップ剤などによる経口投与又は坐剤などによる非経口投与が挙げられる。
【0009】
本発明の解熱剤の投与量は、年齢、体重、症状、投与形態、投与回数等によって異なるが、南天抽出物を有効成分とする場合には、原生薬換算で通常成人に対して1日1g〜10g、南天抽出物(原生薬換算)とアセトアミノフェンを有効成分とする場合には通常成人に対して合計で1日1.15g〜11g、南天抽出物(原生薬換算)とイブプロフェンを有効成分とする場合には通常成人に対して合計で1日1.15g〜10.6gが好ましく、これを1回又は数回に分けて投与するのが好ましい。
【0010】
本発明の解熱剤には、解熱のみを目的として用いてもよいが、必要に応じて例えば、抗炎症剤、鎮痛剤、鎮咳去痰剤、抗アレルギー剤等を配合して総合感冒剤として用いることもできる。
【0011】
【実施例】
以下、実施例を挙げて本発明を詳細に説明するが、本発明はこれらに限定されるものではない。
【0012】
実施例1
Wistar系雄性ラットの正常直腸温を測定後、生理食塩液に懸濁した乾燥酵母懸濁液(20%w/v)を10ml/kgの容量で皮下投与した。翌日、体温上昇が認められたラットに被験薬を経口投与し、以後4時間後まで経時的に直腸温を測定した(図1)。被験薬は、単独投与群には南天実エキス(南天実を30%エタノール水溶液で抽出した後、溶媒を留去した乾燥エキス、以下同じ)250mg/kg(原生薬換算で5g/kg)又はイブプロフェン1mg/kgを、併用投与群には南天実エキス250mg/kg及びイブプロフェン1mg/kgを0.5%CMCに懸濁させ、容量5ml/kgとして投与した。対照群には、0.5%CMCを同容量投与した。
【0013】
投与後4時間までの正常体温を基準にしたときの累積発熱量を発熱係数とし、抑制率、相対指数とあわせて表1に示す。
【0014】
【表1】
【0015】
対照群の発熱係数は平均4.84であったが、イブプロフェン1mg/kg及び南天実エキス250mg/kg単独投与群の発熱係数は、それぞれ平均2.29及び3.37であり、両被験薬の解熱作用が認められた(相対指数:0.472及び0.696)。これら両薬剤の併用投与では解熱作用は更に強く認められ、その相対指数(0.230)は、それぞれ単独投与した時の相対指数の積(0.472×0.696=0.329)よりも小さく、相乗作用が認められた。
【0016】
実施例2
被験薬として、単独投与群には南天実エキス250mg/kg、アセトアミノフェン50mg/kgを、併用投与群には南天実エキス250mg/kg及びアセトアミノフェン50mg/kgを投与した以外は実施例1と同様にして、ラットの直腸温を測定した。結果を図2に、発熱係数、抑制率及び相対指数を表2に示す。
【0017】
【表2】
【0018】
対照群の発熱係数は平均4.97であったが、アセトアミノフェン50mg/kg及び南天実エキス250mg/kgを単独投与した場合、それぞれの発熱係数は平均4.48及び3.88であり、両薬剤は解熱作用を示した(相対指数:0.903及び0.782)。これら両薬剤の併用投与では解熱作用は更に強く認められ、その相対指数(0.530)は、それぞれを単独投与した時の相対指数の積(0.903×0.782=0.706)よりも小さく、相乗作用が認められた。
【0019】
製造例1
アセトアミノフェン900mg、南天実乾燥エキス−30(実施例1で使用したものと同じ)250mg、乳糖218mg、結晶セルロース180mg、カルメロースカルシウム180mg、ヒドロキシプロピルセルロース54mgを攪拌造粒機内で均一に混合した。この混合物にアルコールを添加して造粒し、流動層造粒機で乾燥し、造粒物を整粒機を用いて整粒後、ステアリン酸マグネシウム18mgを混合して打錠用顆粒を調整した。この打錠用顆粒を直径8.0mmの杵を用いて1錠200mgに打錠した。
【0020】
【発明の効果】
南天抽出物は解熱作用を有し、副作用が少なく安全であることから解熱剤として有用である。
【図面の簡単な説明】
【図1】南天実エキス、イブプロフェンの解熱作用を示す図である。
【図2】南天実エキス、アセトアミノフェンの解熱作用を示す図である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to an antipyretic agent.
[0002]
[Prior art and problems to be solved by the invention]
Nanten has long been known for its various medicinal properties, and its fruits and leaves have been heavily used as folk medicine. In particular, domestine contained in fruits has sensory nerve and peripheral nerve palsy effects and is known to be effective in the prevention of asthma, whooping cough, bronchitis, etc. Tablets are commercially available.
In recent years, it has been reported that Nantenin present in Minami Tenjin has a sympathetic nerve blocking action and is effective as a blood pressure lowering agent (Japanese Patent Laid-Open No. 58-183617).
However, it is not known at all that Minami Tenmi has an antipyretic action.
[0003]
On the other hand, various drugs have conventionally been used as antipyretic agents, but most of the substances obtained by chemical synthesis have the disadvantage that side effects such as sleepiness and digestive problems are unavoidable.
[0004]
Therefore, an object of the present invention is to provide a drug having an excellent antipyretic action and high safety.
[0005]
[Means for Solving the Problems]
In view of such a situation, the present inventor has conducted extensive research and found that the Nanten extract has a sustained antipyretic action. Furthermore, when combined with acetaminophen or ibuprofen, it was found that a synergistic antipyretic action was exhibited, and the present invention was completed.
[0006]
That is, this invention provides the antipyretic agent which uses a southern sky extract as an active ingredient.
Moreover, this invention provides the antipyretic agent which uses a south sky extract and acetaminophen as an active ingredient.
Furthermore, this invention provides the antipyretic agent which uses a Nanten extract and ibuprofen as an active ingredient.
[0007]
DETAILED DESCRIPTION OF THE INVENTION
Examples of the southern sky extract used in the present invention include a southern sky fruit and leaf extract, and the southern sky fruit extract is particularly preferable. Here, as the south Tenmi, any of White Minami Tenshin or Akana Minami may be used.
The Nanten extract can be obtained according to a conventional method using water, hot water, an organic solvent or the like. For example, it can be obtained by extracting dried Nanten fruit with ethanol, water, hot water, hydrous ethanol or the like. . What extracted Minami Tenjin with hydrous ethanol, especially 30% ethanol aqueous solution is preferable.
[0008]
In the present invention, a synergistic antipyretic action can be obtained by using a combination of Nanten extract and acetaminophen or ibuprofen. A preferred blending ratio of the Nanten extract (in terms of crude drug) and acetaminophen is 5000: 1 to 1: 100 by weight, and a more preferred blending ratio is 500: 1 to 1:10. Moreover, the preferable compounding ratio of a Nanten extract (raw ingredient conversion) and ibuprofen is 5000: 1 to 1:60 by weight ratio, and a more preferable compounding ratio is 500: 1 to 1: 6.
In addition to the essential components, the antipyretic of the present invention is a pharmaceutically acceptable carrier such as an excipient, a binder, a bulking agent, a disintegrant, a surfactant, a lubricant, a dispersant, a buffer, a preservative, A flavoring agent, a fragrance | flavor, etc. can be used in combination as appropriate. Examples of the dosage form include oral administration such as tablets, capsules, granules, powders, solutions, syrups, and parenteral administration such as suppositories.
[0009]
The dose of the antipyretic of the present invention varies depending on age, body weight, symptom, dosage form, number of administrations, etc., but when the Nanten extract is used as an active ingredient, it is usually 1 g per day for an adult in terms of a crude drug. 10g, 1.15g-11g in total per day for adults when using Nanten extract (converted as bulk drug) and acetaminophen as active ingredients, and Nanten extract (converted as drug substance) and ibuprofen as active ingredients In general, it is preferably 1.15 g to 10.6 g per day for an adult in general, and this is preferably administered once or divided into several times.
[0010]
The antipyretic agent of the present invention may be used for the purpose of antipyretic alone, but may be used as a general cold medicine by blending, for example, an anti-inflammatory agent, an analgesic agent, an antitussive expectorant, an antiallergic agent and the like as necessary. it can.
[0011]
【Example】
EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated in detail, this invention is not limited to these.
[0012]
Example 1
After measuring the normal rectal temperature of Wistar male rats, a dry yeast suspension (20% w / v) suspended in physiological saline was subcutaneously administered in a volume of 10 ml / kg. On the next day, the test drug was orally administered to rats in which an increase in body temperature was observed, and the rectal temperature was measured over time until 4 hours thereafter (FIG. 1). The test drug is either South Tenmichi extract (extracted Minami Tenmi with 30% ethanol aqueous solution and then evaporated to remove the solvent, the same shall apply hereinafter) 250 mg / kg (5 g / kg in terms of drug substance) or ibuprofen. In the combined administration group, 1 mg / kg was suspended in 250 mg / kg of Nanten fruit extract and 1 mg / kg of ibuprofen in 0.5% CMC and administered in a volume of 5 ml / kg. The control group received the same volume of 0.5% CMC.
[0013]
The cumulative calorific value based on the normal body temperature up to 4 hours after administration is defined as the fever coefficient, and the suppression rate and relative index are shown in Table 1.
[0014]
[Table 1]
[0015]
The fever coefficient of the control group averaged 4.84, but the fever coefficient of the
[0016]
Example 2
As a test drug, Example 1 was administered except that the single administration group was administered with 250 mg / kg of Nanten fruit extract and 50 mg / kg of acetaminophen, and the combined administration group was administered with 250 mg / kg of Nanten fruit extract and 50 mg / kg of acetaminophen. In the same manner, the rectal temperature of the rat was measured. The results are shown in FIG. 2, and the exothermic coefficient, inhibition rate, and relative index are shown in Table 2.
[0017]
[Table 2]
[0018]
The fever coefficient of the control group averaged 4.97, but when acetaminophen 50 mg / kg and Nanten fruit extract 250 mg / kg were administered alone, the respective fever coefficients averaged 4.48 and 3.88, Both drugs showed antipyretic action (relative index: 0.903 and 0.782). The antipyretic effect is more strongly observed in the combined administration of these two drugs, and the relative index (0.530) is based on the product of the relative indices when each of them is administered alone (0.903 × 0.782 = 0.706). And a synergistic effect was observed.
[0019]
Production Example 1
Acetaminophen 900 mg, Nanten Real Dry Extract-30 (same as used in Example 1) 250 mg, lactose 218 mg, crystalline cellulose 180 mg, carmellose calcium 180 mg, hydroxypropylcellulose 54 mg were uniformly mixed in a stirring granulator. . The mixture was granulated by adding alcohol, dried with a fluidized bed granulator, granulated using a granulator, and then mixed with 18 mg of magnesium stearate to prepare granules for tableting. . This tableting tablet was tableted into 200 mg tablets using a 8.0 mm diameter punch.
[0020]
【The invention's effect】
Nanten extract is useful as an antipyretic because it has antipyretic action and is safe with few side effects.
[Brief description of the drawings]
FIG. 1 is a graph showing the antipyretic effect of Nanten extract and ibuprofen.
FIG. 2 is a diagram showing the antipyretic effect of Nanten fruit extract and acetaminophen.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16997697A JP4102461B2 (en) | 1997-06-26 | 1997-06-26 | Antipyretic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16997697A JP4102461B2 (en) | 1997-06-26 | 1997-06-26 | Antipyretic |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH1112186A JPH1112186A (en) | 1999-01-19 |
JP4102461B2 true JP4102461B2 (en) | 2008-06-18 |
Family
ID=15896302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP16997697A Expired - Fee Related JP4102461B2 (en) | 1997-06-26 | 1997-06-26 | Antipyretic |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4102461B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4702763B2 (en) * | 2003-07-30 | 2011-06-15 | 塩野義製薬株式会社 | Stable tablets containing crystalline cellulose |
-
1997
- 1997-06-26 JP JP16997697A patent/JP4102461B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JPH1112186A (en) | 1999-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0629400B1 (en) | Idebenone compositions for treating Alzheimer's disease | |
JP4102461B2 (en) | Antipyretic | |
WO1992022307A1 (en) | Remedy for chronic fatigue syndrome | |
JPH0140009B2 (en) | ||
JPWO2014010658A1 (en) | Hihitsu formulation | |
JP2014114253A (en) | Analgesic antiinflammatory composition containing crude drug | |
JP4787499B2 (en) | Pharmaceutical composition | |
JP3982889B2 (en) | Pharmaceutical preparations containing ibuprofen | |
JPH0656677A (en) | Antacid composition | |
JP4203170B2 (en) | Pharmaceutical composition | |
JPWO2005032569A1 (en) | Pharmaceutical composition | |
JP4950551B2 (en) | Gastrointestinal mucosa protective agent | |
JP3734514B2 (en) | Antiulcer agent | |
JP4102460B2 (en) | Antipyretic analgesic anti-inflammatory agent | |
JP5389471B2 (en) | Nasal obstruction inhibitor | |
JP2010047566A (en) | Pharmaceutical composition | |
JP4547892B2 (en) | α-Glucosidase inhibitor | |
JP2010047518A (en) | Rhinostenosis inhibitor | |
EP0182569B1 (en) | Use of 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4H-pyrido[1,2-a]pyrimidine-3-carboxamide for the prevention and treatment of gastrointestinal damages | |
JPH04305527A (en) | Improver for oversensitiveness to cold | |
JPH0535131B2 (en) | ||
JP2007137896A (en) | Ibuprofen-containing pharmaceutical preparation | |
NO871229L (en) | PHARMACEUTICAL MIXTURE CONTAINING OKSAZEPAM. | |
JPH07165593A (en) | Cerebral function improver | |
GB2234898A (en) | Oral pharmaceutical dosage form improving bioavailability |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040413 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20040413 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071023 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080318 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080324 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110328 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120328 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130328 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140328 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |